APOBEC3B and neoplasm: However, in each type of tumor which might be treated by this approach, detailed preclinical histological and toxicological studies should be performed to confirm that heteroclitic T-cell responses against APOBEC3B-mutated neo-epitopes do not raise autoreactive T-cell activity against critically important self-peptide epitopes expressed on the corresponding normal tissues.